^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CYP3A4 overexpression

i
Other names: Cytochrome P450 Family 3 Subfamily A Member 4, Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 4, Cytochrome P450, Family 3, Subfamily A, Polypeptide 4, Albendazole Monooxygenase (Sulfoxide-Forming), 1,4-Cineole 2-Exo-Monooxygenase, 1,8-Cineole 2-Exo-Monooxygenase, Cholesterol 25-Hydroxylase, Albendazole Sulfoxidase, Quinine 3-Monooxygenase, Cytochrome P450 NF-25, Cytochrome P450-PCN1, Cytochrome P450 3A4, Cytochrome P450 3A3, Cytochrome P450 HLp, Nifedipine Oxidase, CYPIIIA3,
Entrez ID:
2ms
Mixed Ru(II)-Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4. (PubMed, Inorg Chem)
Additionally, a synthesized analogue with one [Ru(TPA)]2+ fragment (TPA = tris(pyridin-2-ylmethyl)amine) and two Ir(III) centers, although resistant to photochemical release, showed strong inhibition of CYP3A4 both in purified form and in CYP3A4-overexpressing HepG2 cells, with nanomolar potency. These mixed Ru(II)-Ir(III) compounds can permeate cell membranes and inhibit CYP3A4, presenting a new class of bioactive compounds.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP3A4 overexpression
1year
In vitro simulation of the liver first-pass effect with biotransformation-competent HepG2 cells to study effects of MG-132 on liver and cancer cells. (PubMed, Clin Hemorheol Microcirc)
We successfully established two different culture systems to simulate the liver first-pass effect in vitro. Such systems easily allow to study drug effects simultaneously on liver and on target cancer cells. They are of great value in pre-clinical cancer research, pharmaceutical research and drug development.
Preclinical • Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP3A4 overexpression
|
MG132
over1year
Potency ranking of pyrrolizidine alkaloids in metabolically competent human liver cancer cells and primary human hepatocytes using a genotoxicity test battery. (PubMed, Arch Toxicol)
Finally, experiments in PHH corroborated the genotoxic potency ranking, and revealed genotoxic effects even in the absence of detectable cytotoxicity. In conclusion, our findings strongly support the concept of grouping PAs into potency classes and help to pave the way for a broader acceptance of relative potency factors in risk assessment.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP3A4 overexpression
2years
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. (PubMed, Pharmaceuticals (Basel))
EAI045 and cetuximab combined induce tumor regression in mouse models of EGFR-mutant lung cancer...Our results show that blood-brain barrier ABCB1 can markedly limit EAI045 brain accumulation. Moreover, elacridar coadministration can effectively reverse this process.
Journal
|
EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
EGFR mutation • EGFR T790M • EGFR C797S • CYP3A4 overexpression
|
Erbitux (cetuximab)
2years
Investigation of Radiotracer Metabolic Stability In Vitro with CYP-Overexpressing Hepatoma Cell Lines. (PubMed, Cells)
The optimized protocol, covering cell seeding in 96-well plates and analysis of supernatant by radio thin-layer-chromatography for higher throughput, was transferred to the evaluation of three F-labeled celecoxib-derived cyclooxygenase-2 inhibitors (coxibs)...Comparison with human and murine liver microsome assays showed good agreement with the human metabolite profile obtained by the HepG2 cell lines. Therefore, CYP-overexpressing HepG2 cells provide a good complement for assessing the metabolic stability of radiotracers and allow the analysis of the CYP isoform-specific contribution to the overall radiotracer metabolism.
Preclinical • Journal
|
CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP3A4 overexpression
|
celecoxib oral
over2years
ABCB1 limits brain exposure of the KRAS inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. (PubMed, Pharmacol Res)
The obtained results may help to further optimize the safety and efficacy of sotorasib in clinical use. DATA AVAILABILITY STATEMENT: The data that supports the findings of this study are available in the supplementary material of this article.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP3A4 overexpression
|
Lumakras (sotorasib)
almost3years
Inhibition of phase-1 biotransformation and cytostatic effects of diphenyleneiodonium on hepatoblastoma cell line HepG2 and a CYP3A4-overexpressing HepG2 cell clone. (PubMed, Clin Hemorheol Microcirc)
Other cell functions, including ATP synthesis and consequently the proliferation were negatively affected in both in vitro cell models. Since neither cell integrity nor cell viability were reduced, the effect of DPI in HepG2 can be assessed as cytostatic rather than cytotoxic.
P1 data • Preclinical • Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
CYP3A4 overexpression